Publication|Articles|May 1, 2003

May 2003
Volume 9
Issue 5

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Author(s)Darren Kocs, MD, MHSA, A. Mark Fendrick, MD

Download PDF: Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

over 23 years ago

Article

Lansoprazole Overutilization: Methods for Step-Down Therapy

over 23 years ago

Article

Reducing Costs and Improving Outcomes of Percutaneous Coronary Interventions

over 23 years ago

Article

Evaluation of a Depression Health Management Program to Improve Outcomes in First or Recurrent Episode Depression

over 23 years ago

Article

A Prediction Model for Targeting Low-Cost, High-Risk Members of Managed Care Organizations

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Microplastics Pose Emerging Health, Environmental Risks, With Summer Heat Increasing Exposure

Experts Debate How to Scale Multidisciplinary Care for HFpEF and HFmrEF

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Microplastics Pose Emerging Health, Environmental Risks, With Summer Heat Increasing Exposure

Experts Debate How to Scale Multidisciplinary Care for HFpEF and HFmrEF